About Us

Agenda

Agenda

Agenda
Who we are
History & KOL
Location

About Us

3rd Evolution in the History of Alopecia Treatment,
AGF39 Cytokines

Mesotherapy for Hair Growth

mesotherapy for hair growth,mesotherapy for hair loss

There were three big evolutions in the history of hair loss treatment. Propecia™ and Rogain™ were launched around 1997, and the history of medical hair loss treatment began.

Around 2003, mesotherapy for hair loss was applied to hair loss treatment, resulting in another big progress. Early drug prescriptions for mesotherapy for alopecia were mainly recommended by mesotherapy experts, but were not widely available, with components such as 'Biotin, Dexpanthenol, Zinc Biloba, Centella asiatica, Taurine, and Organic silicium'. Various Multi-nutrients prescriptions acting on the TCA Cycle of cells also began to be used for hair loss treatment in the early 2000s. Until then, the main cause of hair loss was DHT, so it was considered the most important means to inhibit 5αR, a DHT reducing agent.

mesotherapy for hair growth,mesotherapy for hair loss

Around 2007, a new fact called Cytokines, which is secreted by DHT, began to be widely shared as the cause of hair loss. Because direct systemic inhibition of DHT has risk of side effects, if some cytokines can work at the local site as antagonists, it would be an ideal treatment. Since Alopecia mechanism is induced at the skin dermis layer, cytokines therapy for alopecia can be a new progress for hair loss treatment, particularly in cases of male pattern androgenetic alopecia and female pattern androgenetic alopecia.

After launching the professional microneedling products with cytokines for alopecia treatment in 2008, AesMed has supplied it to more than 500 hair care clinics in Korea and has improved its products under the medical advice from the client clinics, doctors of key option leader.

mesotherapy for hair growth,mesotherapy for hair loss

From 2011 to 2014, AesMed conducted three clinical trials at two university medical centers, and the results were announced through Journal of Dermatology, World Congress of Hair Research 2013, and 2014.
AGF39™, concluded prescription of AesMed in 2016, is currently the largest model of similar products in mesotherapy for hair loss, and has become a STANDARD model for competitors' product concepts as well as price policies.
As AesMed's AGF39™, it is estimated that at least 5 million procedures have been performed over the past 18 years, and it is currently the most common meso hair treatment and mesotherapy for hair growth treatment in Korea and Japan.
In this way, AesMed's AGF39™ has become the MESOTHERAPY STANDARD for hair follicle activation, hair follicle regeneration, andhair loss mesotherapy treatment.

TOP